Introduction
============

DNA methylation has a critical role in the regulation of gene expression in tissues and organs ([@awt237-B7]) and its deregulated patterns are increasingly associated with human diseases ([@awt237-B9]; [@awt237-B20]), among which feature a range of neurological disorders ([@awt237-B63]; [@awt237-B26]). In this latter context, epigenetic marks, such as CpG methylation, may be essential because the CNS is a highly specialized structure that requires fine-tuning for gene expression. This is exemplified by the observations that it expresses more alternatively spliced transcripts ([@awt237-B70]) and microRNAs ([@awt237-B6]) than any other tissue, and that three out of four genes are active ([@awt237-B27]). The role of DNA methylation in the function of the CNS has been highlighted by its involvement in memory formation ([@awt237-B38]; [@awt237-B10]; [@awt237-B13]) and ageing-related cognitive decline ([@awt237-B45]). Consequently, increasing interest is now focused on the impact of aberrant DNA methylation patterns in the origin and progression of Alzheimer's disease. This, the most common type of dementia, is characterized by insidious degeneration of brain networks related to memory and cognition. However, few genes are known to be deregulated by DNA methylation in case-control studies of Alzheimer's disease ([@awt237-B58]; [@awt237-B1]; [@awt237-B51]). The explanation for this paucity of results might be associated with the existence of many distinctly functional subregions of the brain that may have different DNA methylation patterns that mask the analyses of the data, a matter that has only recently been addressed, and even then, only for large brain regions ([@awt237-B33]; [@awt237-B67]; [@awt237-B19]; [@awt237-B34]; [@awt237-B8]). Most importantly, even if close to 80% of human genes are expressed in the brain, most of them are expressed in a relatively small percentage of cells (i.e. 70.5% of genes are transcribed in \<20% of all cells) ([@awt237-B35]), an important handicap to discover epigenetically altered genes in specific cells because their DNA methylation patterns could be diluted amongst the majority of cells with different epigenomic patterns. We have addressed this challenging issue by carefully microdissecting the 12 most relevant brain regions of the mouse and hybridizing the corresponding samples to a DNA methylation microarray. The observed DNA methylomes were used to identify aberrant DNA methylation changes that occurred in two mouse models of Alzheimer's disease and to translate these findings to patients with Alzheimer's disease.

Materials and methods
=====================

Mice samples
------------

Brain region profiles were derived from C57BL/6J mice obtained from the Charles River laboratories. Twelve P60 samples (three female and three male samples for the array hybridization and three female and three male samples for the pyrosequencing validation) were used. Mice were killed by cervical dislocation, and their brains were dissected out within the first 2 min post-mortem and kept at −80°C. Brain areas were dissected from cryostat brain sections (−20°C) with the help of a ×5 magnifying lens, following their stereotaxic coordinates ([@awt237-B50]), as previously described ([@awt237-B52]; [@awt237-B48], [@awt237-B49]). For validations of epigenetically deregulated genes in Alzheimer's disease, frontal cortex samples from two transgenic models were used, namely APP/PSEN1 ([@awt237-B5]) and 3xTg-AD ([@awt237-B43]) mice. Five 12-month-old AβPP/PS1 and five wild-type littermates, and three 18-month-old 3TG and three 3TG control mice, were assayed for DNA methylation using the mouse brain genome-wide promoter DNA methylation array. Additionally, independent sets of 12-month-old AβPP/PS1 and five wild-type littermates, and three 18-month-old 3TG and three 3TG control mice were used for pyrosequencing validations and RNA assays. Four APP/PS1 and four wild-type animals were deeply anaesthetized by intraperitoneal injection (0.2 ml/10 g body weight) with a mixture of ketamine (100 mg/kg) and xylazine (20 mg/kg) before intra-cardiac perfusion with 4% paraformaldehyde in PBS. Brains were removed, post-fixed in the same fixative for 4 h and processed for immunohistochemistry. Another group of four APP/PS1 and four wild-type mice were sacrificed by decapitation and their brains quickly removed, dissected on ice and immediately frozen and stored at −80°C until processing for the immunoblot analysis. All animals were maintained under standard animal house conditions in a 12-h dark-light cycle with free access to food and water. The experimental procedures complied with the European guidelines for the care and use of laboratory animals (EU directive 2010/63/EU) and were approved by the local ethics committee (UB-IDIBELL).

Human samples
-------------

Post-mortem tissues were obtained from the IDIBELL Biobank, which is part of the eBrainNet Europe Bank (<http://www.brainnet-europe.org/>) 'Network of Excellence' funded by the European Commission in the 6th Framework Program 'Life Science' (LSHM-CT-2004-503039); the CIEN Tissue Bank, CIEN Foundation, Instituto de Salud Carlos III; and the University of California Irvine Alzheimer Disease Research Centre, UCI Institute for Memory Impairments and Neurological Disorders. The collection of all samples conformed to the relevant regulations, ethical considerations and legislation as defined by the European Union and Spain. Samples were dissected and characterized for Braak stage before further examination. DNA and RNA from grey matter samples of frontal cortex were extracted for pyrosequencing and RNA assay validations. Only samples with RIN\>6.5 according to the RNA quality test developed using the Agilent 2100 bioanalyzer were included in the study. These filtered samples were DNA and RNA from grey matter of frontal cortex (Brodmann area 9) of 20 controls \[65% female; age 71 ± 3 years, post-mortem interval delay (PMI) 9 ± 1 h, mean ± SEM\] and 20 Alzheimer's disease Braak stage V-VI (70% female; age 82 ± 2 years, PMI 8 ± 1 h, mean ± SEM) samples matched for age and gender. [Supplementary Table 1](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1) describes in detail the available clinicopathological information for all cases and controls (Braak staging, PMI, age and gender). The PMIs were similar for both groups.

Bisulphite conversion of DNA
----------------------------

The Repli-g whole genome-amplification kit (Qiagen) was used to generate non-methylated DNA following the manufacturer's protocol. For methylated DNA, part of the resulting DNA was *in vitro* methylated using SssI enzyme (New England Biolabs). The EZ DNA methylation kit (Zymo Research) was used for bisulphite conversion of all DNA samples used, according to [@awt237-B3].

Mouse brain genome-wide promoter DNA methylation array
------------------------------------------------------

The mouse brain genome-wide promoter DNA methylation array is a custom designed Illumina's VeraCode GoldenGate DNA methylation assay that was specifically enriched in genes related with sensory perception, cognition, neuroplasticity, brain physiology and mental diseases in order to provide a useful tool for subsequent neurological studies. From the starting list of 762 genes we downloaded the transcription start coordinates from <http://genome.ucsc.edu> using 2007 July mm9 assembly and UCSC Genes track. From genes with more than one transcription starting site we selected the first at the 5\' end of the gene. We took 750 bp upstream (5\') and 250 bp downstream (3\') relative to the marked transcription site to design the specific probe for the array, which was subsequently filtered for single mapping on its specific chromosome position. The 384 genes with the highest scores were included in the final design of the array ([Supplementary Table 2](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1)). Among the 384 amplicons, the average of interrogated CpGs was 2.7 ([Supplementary Table 2](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1)).

Data analysis
-------------

All data were analysed using the open-source statistical programming language R (version 2.13.1). Quantile normalization of the array was carried out using the lumi package and posterior analysis was done with the genefilter package (Bioconductor). For general analysis, all probes with detection values of *P* \< 0.01 in \>15% of the samples (25 probes) and probes located on chromosome X (17 probes) were excluded. Poor-quality samples (\>10% failed probes) were also excluded. For unsupervised clustering analysis, probes with a general standard deviation \<0.05 were excluded as non-informative. Subsequently, heatmaps were analysed using the gplots package. Spectral map analysis was carried out using the mpm package ([@awt237-B65]). Statistical analysis was performed using the lumi package (Mann-Whitney and Kruskal-Wallis tests for two- and multiple-group comparisons, respectively, adjusting *P*-values with the FDR algorithm).

Pyrosequencing
--------------

The set of primers for PCR amplification and sequencing ([Supplementary Table 3](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1)) were designed using the PyroMark assay design program, version 2.0.01.15 (Qiagen); amplification primers hybridize with CpG-free sites to ensure a methylation-independent reaction and one primer (opposite the sequencing primer) is biotinylated to convert the PCR product to single-stranded DNA templates. We used 1 µl of bisulphite-treated DNA for each PCR. In order to prepare single-stranded PCR products, we used the Vacuum Prep Tool (Qiagen), following the manufacturer's instructions. Pyrosequencing reactions and methylation quantification were performed in a PyroMark Q24 System version 2.0.6 (Qiagen). All pyrosequencing assays were run in triplicate. These technical replicates yielded standard errors of means \<1%.

Real-time polymerase chain reaction
-----------------------------------

Total RNA purification and DNase treatment were performed using TRIzol (Invitrogen) and the Turbo DNA-Free kit (Ambion). RNA was reverse-transcribed using the Thermoscript RT-PCR system (Invitrogen) and each PCR was carried out in triplicate using SYBR Green PCR MasterMaster Mix (Applied Biosystems). Thermocycling conditions were 10 min at 95°C, then 50 cycles of 15 s at 95°C and 1 min at 60°C. Fluorescent signals were acquired by the ABI Prism 7900HT Sequence Detection System (Applied Biosystems), and positive standard deviations were normalized using three housekeeping genes (*GUSB*, *RPL38* and *TBP*). The primers for real-time PCR are listed in [Supplementary Table 4](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1). PCR efficiencies were calculated using standard dilutions and the LinReg software ([@awt237-B54]).

Immunofluorescence and confocal microscopy
------------------------------------------

Tissue samples were embedded in paraffin and 4 -µm coronal sections were cut with a microtome. De-waxed sections were stained with a saturated solution of Sudan Black B (Merck) for 30 min to block the autofluorescence of lipofuscin granules present in cell bodies, then rinsed in 70% ethanol and washed in distilled water. The sections were treated with citrate buffer to enhance antigenicity, and then incubated at 4°C overnight with primary antibodies against Tbxa2r (1:200, rabbit; Acris), F2rl2 (1:50, rabbit; Santa Cruz), Sptbn4 (1:100, rabbit; Sigma-Aldrich). After washing, the sections were incubated with Alexa488 (1:400, Molecular Probes) fluorescence secondary antibody against the corresponding host species. After counterstaining of nuclei with DRAQ5TM (1:2000, Biostatus), the sections were mounted in Immuno-Fluore Mounting medium (ICN Biomedicals), sealed, and dried overnight. Sections were examined with a Leica TCS-SL confocal microscope. The protein levels were evaluated by densitometric quantification in reference to the GFAP immunostained area in five representative pictures taken from the neocortex of each animal using Adobe® Photoshop® CS4.

Immunoblot analysis
-------------------

Frozen cortical areas were dounce-homogenized in lysis buffer (50 mM Tris/HCl buffer, pH 7.4 containing 2 mM EDTA, 0.2% Nonidet P-40, 1 mM PMSF, protease and phosphatase inhibitor cocktails, Roche Molecular Systems), incubated for 20 min with agitation at 4°C and centrifuged for 30 min at 16 000 *g*. The supernatant was recovered and stored at −80°C. Protein content was determined by the BCA method (Thermo Scientific). Equal amounts of protein (20 µg per lane) were separated by SDS-PAGE (10%) and transferred onto nitrocellulose membranes (Amersham, GE Healthcare). Non-specific bindings were blocked by incubation in 5% non-fat milk in Tris-buffered saline (100 mM NaCl, 10 mM Tris, pH 7.4) containing 0.2% Tween (TTBS) for 1 h at room temperature. Afterwards, membranes were incubated overnight at 4°C with the polyclonal mouse anti-SORBS3 (1:1000, Abnova) in TTBS with 3% bovine serum albumin. Protein loading was monitored using a mouse monoclonal antibody against β-actin (1:30 000, Sigma-Aldrich). Membranes were then incubated for 1 h in the appropriate horseradish peroxidase-conjugated secondary antibodies (1:2000, Dako) and immunocomplexes were revealed by an enhanced chemiluminescence reagent (ECL AdvanceTM, Amersham Biosciences). Densitometric quantification was carried out with TotalLab v2.01 software (Pharmacia). Protein bands were normalized to β-actin levels and expressed as a percentage of the control group level.

Results
=======

We first carefully microdissected the 12 most relevant brain regions of the mouse (cerebellar granular and Purkinje layers, frontal cortex, hippocampal regions CA1, CA3 and dentate gyrus, basolateral amygdala, caudatus putamen, substantia nigra, hypothalamus, globus pallidus and thalamus) and hybridized the corresponding DNAs obtained to a custom microarray containing the 5'-end regulatory regions of 384 mouse genes ([Supplementary Table 2](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1)). The list was specifically enriched in genes related to sensory perception, cognition, neuroplasticity, brain physiology and mental diseases. The CpG probes used were mapped to locations between −750 bp and +250 bp of the corresponding transcription start sites. Among the 384 amplicons, the average of interrogated CpGs was 2.7. To test the reliability of the array we used three different technical replicates randomly distributed on the array. After quantile normalization, we obtained excellent coefficients of correlation (r^2^= 0.98, 0.99 and 0.99, [Supplementary Fig. 1](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1)) confirming the high reliability of the method. Two important control samples were also included: DNA fully methylated *in vitro* using the SssI enzyme (New England Biolabs), as a positive methylated control for all CpG sites, and a whole genome PCR amplified DNA obtained using the Repli-g whole genome-amplification kit that does not retain methylated CpGs (Qiagen), as a negative methylated control for all CpG sites. The VeraCode assay recognizes the SssI-treated DNA as highly methylated and the whole genome amplified DNA as fully unmethylated ([Supplementary Fig. 2A](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1)). We also interrogated the linear capacity of the array, mixing different proportions of methylated and unmethylated DNA generating a set of five different ratios (1:0, 2:1, 1:1, 1:2 and 0:1). The use of the above described whole-genome amplified DNA as a negative control and *in vitro* methylated DNA as positive control DNA obtained a high Pearson's coefficient of correlation (r^2^= 0.97, [Supplementary Fig. 2B](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1)). We further validated the VeraCode assay as a tool to measure DNA methylation by the existence of inactivation of one X-chromosome in females by DNA methylation, when compared with the unmethylated X-chromosome in males. Herein, we observed that those CpG sites located in the X-chromosome in the VeraCode assay were able to discriminate between female and male samples in brain regions ([Supplementary Fig. 2C](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1)).

To further validate the array data (obtained using three female and three male samples), we took advantage of the spectral map analysis ([Supplementary Fig. 3A](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1)) and performed pyrosequencing of the most discordant regions for each of the genes identified using an additional set of biological samples (a distinct group of three female and three male samples). Herein, we obtained similar ratios between both techniques and high overall correlation (r^2^= 0.721, [Supplementary Fig. 3B](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1) and [C](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1)). In addition, we interrogated the biological relevance of such DNA methylation correlating these data with the RNA expression profiles available in Allen Brain Atlas database ([Supplementary Fig. 4](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1)). In this regard, we obtained an excellent correlation between both sets of values (Fisher's exact test *P* \< 0.001) underlying its biological significance. Using this approach, we identified 72 genes ([Supplementary Table 5](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1)) that were significantly differentially methylated (FDR \< 0.05) across the described 12 brain regions of C57BL/6J mice, enabling them to be distinguished by the hierarchical clustering approach ([Fig. 1](#awt237-F1){ref-type="fig"}). The observed differences were not associated with cellular heterogeneity at the level of glia versus neuron lineage. When these two cell types were isolated in the mouse brain using A2B5 and PSA-N-CAM antibodies, respectively, followed by magnetic separation ([@awt237-B56]; [@awt237-B60]) no significant differences in DNA methylation were observed for seven studied genes (Spearman's correlation test, rho = 0.60, *P* = 0.166; [Supplementary Fig. 3D](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1)). Interestingly, the cluster analysis identified three main DNA methylation branches corresponding to cerebellum (granular cell layer and Purkinje cells), cerebral cortex (CX, CA1, CA3 and dentate gyrus) and diencephalon-basal ganglia (basolateral amygdala, caudate-putamen, substantia nigra, hypothalamus, globus pallidus and TH). These largely correspond with the major divisions of the brain into hindbrain, forebrain and midbrain ([Fig. 1](#awt237-F1){ref-type="fig"}). Thus, consistent with the previously reported RNA expression profiles ([@awt237-B27]; [@awt237-B35]), our results suggest that major brain divisions are not only structural bisections but also have distinct functional significance. These DNA methylation patterns also reflect the cell type composition of these regions: diencephalon-basal ganglia, which are mainly enriched in GABAergic neurons, and cerebral cortex, which is enriched in glutamate neurons, cluster according to their cell characteristics ([Fig. 1](#awt237-F1){ref-type="fig"}). DNA methylation microarray data for 384 genes in the 12 studied mouse brain regions are available to download from NCBI Gene Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo>): GSE47038. Figure 1Unsupervised heatmap clustering of a genome-wide promoter DNA methylation microarray across 12 brain regions in the C57BL/6 mouse. A schematic representation of studied regions was performed on plates adapted from the mouse brain in a stereotaxic coordinates atlas. The circles and areas mark sites from which brain tissue was dissected. The frontal cortex (distance from the bregma, +2.68), caudate-putamen (+0.98), basolateral amygdala (−0.90 to −0.95), hypothalamus (−0.82), globus pallidus (−1.20), thalamus (−1.34), hippocampus (−1.94, hippocampal field CA3, CA1 and dentate gyrus, DG), midbrain area (substantia nigra + ventral tegmental area, −3.08), and cerebellum (−5.80, granular cell layer, GCL; Purkinje cells, PC) were microdissected. Red and green colours indicate high and low levels of DNA methylation, respectively. Scale bars = 1 mm.

The DNA methylation clustering analyses that recognize cerebral cortex as a distinct branch are relevant to our understanding of Alzheimer's disease because this is the region most strongly affected in the disorder. Thus, we made a detailed comparison of the DNA methylation patterns in cerebral cortex and the rest of the brain, the latter being regions that are not targeted in Alzheimer's disease. We identified 52 genes that were differentially methylated between cerebral cortex and the rest of the brain ([Supplementary Table 6](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1)) (FDR \< 0.05) and further investigated the seven genes with the greatest differential methylation ([Fig. 2](#awt237-F2){ref-type="fig"}A). For six of these seven (86%) genes, we were able to link the presence of high levels of DNA methylation at their 5'-end regions with downregulation of the corresponding transcripts measured by quantitative real time-PCR ([Fig. 2](#awt237-F2){ref-type="fig"}B), highlighting the functional relevance of the observed epigenetic differences. To determine if these genes underwent DNA methylation changes in the disorder, we hybridized the frontal cortex samples from two well-established models of Alzheimer's disease in mice, APP/PSEN1 and 3xTg-AD ([@awt237-B5]; [@awt237-B43]) to the DNA methylation microarray. Strikingly, we observed that thromboxane A2 receptor (Tbxa2r), coagulation factor II (thrombin) receptor-like 2 (F2rl2), sorbin and SH3 domain containing 3 (Sorbs3) and spectrin beta 4 (Spnb4) were hypermethylated in the frontal cortex of APP/PSEN1 mice observing a similar trend in 3xTg-AD mice ([Fig. 2](#awt237-F2){ref-type="fig"}C). DNA methylation microarray data for the 384 genes in the frontal cortex samples from control animals and the two transgenic models APP/PSEN1 and 3xTg-AD are available to download from NCBI Gene Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo>): GSE47036. Figure 2Epigenetic deregulation of target genes in Alzheimer's disease brain regions in mice. Differential DNA methylation (**A**) and RNA expression (**B**) for the top seven candidate genes that discriminate cerebral cortex from the rest of the brain (control C57BL/6 mouse). Differential 5'-end DNA methylation patterns for *Tbxa2r*, *F2rl2*, *Sorbs3* and *Spnb4* according to DNA methylation microarray values (**C**) and pyrosequencing (**D**) in the frontal cortex of APP-PSEN1 and 3xTg-AD Alzheimer's disease mouse models in relation to their corresponding controls. Pyrosequencing values presented correspond to the average CpG methylation across each amplicon. The gain of promoter hypermethylation for *Tbxa2r*, *F2rl2*, *Sorbs3* and *Spnb4* in the frontal cortex of APP-PSEN1 and 3xTg-AD Alzheimer's disease mouse models is associated with the downregulation of the corresponding RNA transcripts (**E**) and proteins, measured by western blot (**F**) and immunofluorescence (**G**). \**P* \< 0.05 in the Student's *t*-test.

To achieve biological replication of the data obtained with the first group of samples, we confirmed the hypermethylation of the four genes identified above using an additional set of samples from the frontal cortex of APP/PSEN1 and 3xTg-AD mice using a different DNA methylation technique, pyrosequencing ([Fig. 2](#awt237-F2){ref-type="fig"}D). The presented pyrosequencing values correspond to the average level of CpG methylation across each amplicon and [Supplementary Fig. 5](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1) shows methylation values for each CpG within the studied amplicons. In these cases, we also linked the presence of the hypermethylation events in the cortex from the Alzheimer's mouse models to the downregulation of the corresponding transcripts ([Fig. 2](#awt237-F2){ref-type="fig"}E) and proteins in the western blot of *F2rl2*, *Sorbs3* and *Spnb4* genes ([Fig. 2](#awt237-F2){ref-type="fig"}F and [Supplementary Fig. 6](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1)) and immunofluorescence of *Tbxa2r* ([Fig. 2](#awt237-F2){ref-type="fig"}F and G).

These encouraging results prompted us to investigate human biological samples to address whether the observed epigenetic changes occurred in patients with Alzheimer's disease. We used pyrosequencing to analyse the DNA methylation status of the four validated genes (from which gain of 5\`-end methylation was associated with diminished expression in the Alzheimer's disease mouse models) in a collection of 20 frontal cortex samples from Alzheimer's disease Braak stage V-VI cases, comparing them with 20 aged-matched control samples. As in the mouse models, TBXA2R, SORBS3 and SPTBN4 were hypermethylated in the human Alzheimer's frontal cortex samples ([Fig. 3](#awt237-F3){ref-type="fig"}A). The pyrosequencing values presented correspond with the average level of CpG methylation across each amplicon and [Supplementary Fig. 7](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1) shows methylation values for each CpG within the studied amplicons. We found an association between the gain in hypermethylation of TBXA2R, SORBS3 and SPTBN4 in the frontal cortex of the patients with Alzheimer's disease with a reduction of the corresponding RNA transcripts ([Fig. 3](#awt237-F3){ref-type="fig"}B) and proteins ([Fig. 3](#awt237-F3){ref-type="fig"}C), reinforcing the biological role of the identified epigenetic events. Finally, we found a similar trend for F2RL2 DNA methylation and RNA expression although the great variability of expression among samples precluded a definitive conclusion for this gene. Figure 3Epigenetic deregulation of target genes in the frontal cortex of patients with Alzheimer's disease. The gain of promoter hypermethylation for the TBXA2R, SORBS3 and SPTBN4 genes in the Alzheimer's disease frontal cortex determined by pyrosequencing (**A**) (pyrosequencing values presented correspond to the average CpG methylation across each amplicon) is associated with the downregulation of the corresponding RNA transcripts (**B**) and proteins, measured by overall immunofluorescence (**C**). The same trend is observed for F2RL2, but was not statistically significant. \**P* \< 0.05 in the Student's *t*-test.

It is worth mentioning that the 5'-ends of the human counterparts (F2RL2, SORBS3, SPTBN4 and TBXA2R) of the mouse genes (*F2rl2*, *Sorbs3*, *Spnb4* and *Tbxa2r*) validated as targets of epigenetic disruption in Alzheimer's disease show structural and functional homologies ([Supplementary Fig. 8](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1)). In addition to the chromosomic location of the corresponding homologous regions between humans and mice, the 5'-ends of these four genes share, in both species, a high number of identical transcription factor binding sites ([Supplementary Fig. 8A](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1)). Interestingly, this observation is particularly true for the nucleotide regions that contain the CpG dinucleotides assessed by the DNA methylation microarray and pyrosequencing ([Supplementary Fig. 8B](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1)). Most importantly, four of the transcription factor binding sites common in both species, and located precisely within the CpGs with differential DNA methylation between cases and controls, show methylation-sensitive binding affinity. These sites were TFAP2A ([@awt237-B32]), TBP ([@awt237-B2]), GATA-2 ([@awt237-B53]) and GATA-3 ([@awt237-B23]) ([Supplementary Fig. 8C](http://brain.oxfordjournals.org/lookup/suppl/doi:10.1093/brain/awt237/-/DC1)). In this regard, for promoters without a CpG island, the methylation of particular CpG sites surrounding the transcription start sites can also be linked with transcriptional downregulation ([@awt237-B16]; [@awt237-B28]; [@awt237-B46]). These findings warrant further research in this area.

Discussion
==========

As mentioned previously, ∼80% of total genes are expressed in the brain and most are expressed in a relatively small percentage of cells ([@awt237-B35]). It is an important handicap to elucidate epigenetically deregulated genes in CNS because the characteristic patterns that regulate the expression of concrete genes in specific cells are presumably diluted inside a majority of cells governed by alternative epigenetic patterns. Furthermore, we should consider that neurons show a high variation in DNA methylation profiles according to their unique characteristics ([@awt237-B25]). An additional complication arises from the interindividual variation observed in humans which also contributes to mask such differences. These make the discovery of epigenetic alterations in neurological diseases difficult and, as consequence, few genes have, to date, been reported in widespread non-tumoral disorders such as Alzheimer's disease ([@awt237-B58]; [@awt237-B74]; [@awt237-B1]; [@awt237-B51]).

To face this challenge, we focused on genetically homogeneous mouse models because they show a reduced interindividual variation. In spite of the importance of mice models in scientific research, no platforms interrogating mouse DNA methylation have been commercialized and the available alternatives are not sensitive enough to quantify the expected DNA methylation differences in CNS (a comparison of methods is available in [@awt237-B17]). For that, we designed a custom Illumina VeraCode DNA methylation mouse array enriched in genes related to sensory perception, cognition, neuroplasticity, brain physiology and mental diseases. Illumina platforms have been demonstrated to be accurate genome-wide assays, commonly used to study DNA methylation ([@awt237-B4]), and, as consequence, our custom array could be a useful tool to identify DNA methylation differences in mouse brain. However, there is the limitation that only the DNA sequences included in the microarray can be studied and the enrichment of candidate genes selected for their putative role on neurological pathways creates a bias for these types of candidates. Additionally, we have confined our study to the sequences 750 bp upstream and 250 bp downstream of the corresponding transcription start sites and CpGs located in other intragenic or intergenic DNA methylation regions, which could also have an impact on gene activity. Importantly, there are new challenges in the study of DNA methylation in the brain and its disorders that should be considered, such as the presence of hydroxymethylation ([@awt237-B31]; [@awt237-B41]; [@awt237-B59]; [@awt237-B61]; [@awt237-B30]) which, unfortunately, cannot be distinguished by standard bisulphite conversion ([@awt237-B21]) or the recognition that DNA methylation is a dynamic process in brain regions, including those associated with cognition and behaviour ([@awt237-B72]; [@awt237-B73]). In our study, we accomplished a detailed description of DNA methylation profiles of 12 well-defined mouse brain regions and used this information to highlight the specific characteristics of affected regions in Alzheimer's disease. Thus, we identified a subset of possible target genes for Alzheimer's disease that were interrogated in two different Alzheimer's mouse models and human samples achieving a high correlation between the groups.

The DNA hypermethylation-associated inactivation of the TBXA2R, F2RL2, SORBS3 and SPTBN4 genes discovered here in samples of Alzheimer's disease could provide additional clues to understand the pathology of the disease. TBXA2R is a member of the family of G protein-coupled receptors that regulates the cAMP response element-binding protein (CREB) ([@awt237-B40]; [@awt237-B42]). In this regard, the CREB activation pathway is critical for neuron activity ([@awt237-B11]). It has been recently observed that other CREB-related genes are differentially methylated across different cortex regions and cerebellum ([@awt237-B8]) and CREB-signalling alterations occur in Alzheimer's disease ([@awt237-B55]). TBXA2R plays another important role in the pathobiology of Alzheimer's disease by mediating NMDA excitotoxicity ([@awt237-B39]). NMDA treatment induces apoptosis and the production of thromboxane A2 (TXA2) ([@awt237-B44]). The ligand of TBXA2R establishes a link between NMDA excitotoxicity and TXA2 signalling. Interestingly, amyloid-β treatments also induce TXA2 production and are associated with neurodegeneration, which is, in turn, attenuated by TXA2 antagonists ([@awt237-B68]). It is also important to mention that F2RL2, identified in the Alzheimer's mice models but not completely validated in the human samples, is also associated with NMDA excitotoxicity and is necessary for the APC-mediated protection after NMDA treatments ([@awt237-B12]). The second identified target of epigenetic inactivation, SORBS3, is a gene previously reported to be hypermethylated in Alzheimer's disease ([@awt237-B58]). SORBS3, also known as vinexin, is involved in synapsis ([@awt237-B24]) and regulates gene expression ([@awt237-B37]) and further research is necessary to understand its putative role in Alzheimer's disease.

Finally, the third candidate, SPTBN4, is a prominent member of the axon initial segment and, in combination with the ankyrin G protein, acts as a bridge between the cytoskeleton and voltage-gated channels ([@awt237-B14]). The correct formation of the axon initial segment is essential for synaptic integration and the firing of the action potential ([@awt237-B47]; [@awt237-B29]) and its disruption compromises neuronal function, organization and polarity ([@awt237-B18]). Indeed, Spnb4 mutant mice fail to initiate action potentials and show progressive behavioural deficits with altered network excitability ([@awt237-B62]; [@awt237-B69]; [@awt237-B64]). Most importantly for Alzheimer's disease, the integrity of the axon initial segment is necessary to maintain the axonal localization of tau ([@awt237-B36]) and its disruption could result in tau mislocalization, increase of tau presence in the somatodendritic compartment and enhanced exposure to kinases. In this regard, SPTBN4 also anchors CAMKII to the axon initial segment ([@awt237-B22]), and, thus, CAMKII mislocalization upon SPTBN4 epigenetic loss could cause tau hyperphosphorylation, a common finding in Alzheimer's disease ([@awt237-B66]). Supporting this hypothesis, RNA interference of the SPTBN4 orthologue in a *Drosophila* Alzheimer's disease model also enhances tau toxicity ([@awt237-B57]). In addition, the mutant mice for ankyrin G (the partner of Spnb4 in axon initial segment) shows neurodegeneration ([@awt237-B71]), reinforcing the importance of axon initial segment integrity in neuronal viability. Interestingly, the DNA-methylation associated loss of SPTBN4 identified here could also contribute to Alzheimer's disease by another pathway: the alteration of amyloid precursor protein processing. Alpha and beta-secretases, which are responsible for non-amyloidic and amyloidic processing of amyloid precursor protein, tend to localize in the somatodendritic compartment and plasmatic membrane, respectively (reviewed in [@awt237-B15]). In this context, the non-amyloidic processing of amyloid precursor protein occurs predominantly on the cell surface and could depend on the integrity of the axon initial segment that could be disrupted by SPTBN4 epigenetic silencing. Thus, the observed DNA methylation-associated inactivation of SPTBN4 could relate to both tau hyperphosphorylation and an increase in the amyloidic processing of amyloid precursor protein, the two main hallmarks of Alzheimer's disease.

Overall, our data suggest that key genes are altered by DNA methylation in Alzheimer's disease, highlighting the disruption of particular molecular signalling pathways and cellular structures, such as CREB-activation and the axon initial segment.
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